Isolated in 1991 by Predrag Sikirić and colleagues at the University of Zagreb from a protective protein found in human gastric juice. "BPC" stands for Body Protection Compound; the 15-amino-acid fragment labeled "157" has been the focus of nearly all published research since.

BPC-157 upregulates growth factor receptors — particularly VEGFR2 — driving angiogenesis (new blood vessel formation) at injury sites. It also modulates nitric oxide signaling and interacts with the dopaminergic, serotonergic, and GABAergic systems, which helps explain its gut-brain axis effects. Mechanistically it accelerates the transition from inflammation to proliferation in the wound-healing cascade.

Animal models are extensive. Staresinic et al. (2006) demonstrated accelerated Achilles tendon transection repair in rats. Cerovecki et al. (2010) and Chang et al. (2011) showed tendon-to-bone healing improvements. Klicek et al. (2013) documented gastrointestinal fistula closure. Boban-Blagaic et al. (2008) reported reversal of SSRI-induced GI damage. Additional rat studies have covered muscle laceration, ligament injury, bone defects, and traumatic brain injury.

Human data is very limited — mostly case reports and small observational series in GI conditions. No large randomized trials exist, which is the most important caveat.

TB-500 (systemic repair complement), GHK-Cu (collagen and connective tissue quality), KPV (inflammatory damping, especially in gut protocols).

Thymosin Beta-4 (Tβ4) was first isolated from calf thymus in 1981 by Low and Goldstein. TB-500 is the synthetic C-terminal fragment of Tβ4 that carries most of its regenerative activity and became the preferred research form due to better stability.

TB-500 binds G-actin — a cytoskeletal protein involved in cell shape and migration. That binding promotes cell migration to injury sites, upregulates laminin-5, and drives angiogenesis. Unlike localized agents, it acts systemically: injected anywhere, it distributes broadly to circulate healing signals throughout the body.

Animal models are well-developed. Crockford et al. (2010) showed cardiac regeneration after myocardial infarction in mice. Sosne and colleagues published a long series on corneal epithelial repair from 2005 onward. Goldstein et al. documented dermal wound healing, and TB-500 has been widely studied in equine performance and injury recovery literature.

Human data is limited. A clinical formulation of full-length Tβ4 (RGN-259) has moved through Phase 2/3 trials for dry eye and corneal wounds, which is the closest direct human evidence.

BPC-157 (local + systemic recovery), GHK-Cu (collagen quality), KPV (for inflammation-heavy injuries).

Isolated from human plasma in 1973 by Loren Pickart, who observed that plasma from younger donors had regenerative effects on aged liver tissue. The active agent turned out to be a tripeptide (glycyl-histidyl-lysine) bound to copper. Plasma levels of GHK drop roughly 60% between age 20 and age 60 — the observation that launched decades of research.

GHK-Cu is a copper carrier and a transcriptional modulator. Pickart and Margolina's 2012 gene array work showed it influences expression of roughly 4,000 human genes — shifting expression patterns away from aged/damaged profiles toward healthier, regenerative ones. Downstream it stimulates collagen and elastin synthesis, upregulates decorin (tissue quality), and suppresses several inflammatory signaling pathways.

Animal and in vitro research is extensive. Maquart et al. (1988) demonstrated wound healing acceleration. Trachy et al. (1990) showed hair follicle stimulation. Pickart and colleagues have published on gene expression reset, stem cell stimulation, and skin regeneration over decades.

Human data exists primarily for topical use — multiple trials show improvements in skin firmness, wound healing, and age-related skin quality. Injectable human research is limited but clinical use is widespread.

BPC-157 and TB-500 (repair protocols), KPV and Thymosin Alpha-1 (immune/inflammation stacks). Also widely used topically alongside injectable protocols.

Isolated from the thymus gland in 1977 by Allan Goldstein and Abraham White at Albert Einstein College of Medicine. The full 28-amino-acid sequence was synthesized in 1979, and the compound has been studied continuously since — now approved as Zadaxin in over 35 countries for chronic hepatitis B, hepatitis C, immunodeficiency, and as an adjunct in certain cancers.

Ta1 acts primarily on the adaptive immune system. It binds Toll-like receptors (particularly TLR2 and TLR9) on dendritic cells, enhances maturation of T-cells in the thymus, increases NK-cell cytotoxicity, and helps balance Th1/Th2 polarization. The net effect is immune normalization — it restores function in blunted immune systems without overactivating healthy ones, which is why it's described as a modulator rather than a stimulator.

Human clinical evidence is unusually robust for a peptide. Andreone et al. (2001) and Sherman et al. (1998) documented efficacy in chronic hepatitis B and C. A meta-analysis by Wu et al. (2013) found Ta1 reduced mortality in severe sepsis. More recently, Liu et al. (2020) and related ICU studies reported reduced mortality in severe COVID-19 when Ta1 was added to standard care — including reversal of T-cell exhaustion.

Additional trials cover melanoma adjunct therapy, vaccine response in the elderly, and chronic immune deficiency. The body of evidence is larger than almost any other research peptide.

KPV (adaptive + innate immune coverage), GHK-Cu (gene-level anti-inflammatory support), BPC-157 (tissue repair in chronic inflammatory conditions).

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). Researchers in the 1990s and early 2000s characterized it as the anti-inflammatory "active site" of the larger hormone — it retains most of the anti-inflammatory activity of α-MSH without the pigmentation and cardiovascular effects of the full peptide.

KPV inhibits NF-κB, the master regulator of inflammatory gene transcription. That suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and calms overactive macrophages and mast cells. Critically, KPV is transported into cells via PepT1 — a peptide transporter heavily expressed in the gut — which concentrates its effect on intestinal epithelium and makes it particularly useful for GI inflammation.

Animal and in vitro work is the primary evidence base. Kannengiesser et al. (2008) demonstrated colitis reduction in mouse models. Dalmasso et al. (2008) showed targeted nanoparticle delivery of KPV was highly effective in experimental IBD. Multiple papers have documented effects in skin inflammation, ocular inflammation, and joint models.

Human research is limited to early-stage work and off-label clinical use, primarily in IBD and chronic inflammatory conditions. The mechanistic case is strong; the formal clinical trial base is still developing.

BPC-157 (gut repair protocols — the two are highly complementary), Thymosin Alpha-1 (immune dysregulation), GHK-Cu (broad anti-inflammatory stacks).

Developed by ConjuChem in the early 2000s. The Drug Affinity Complex (DAC) version was published in Teichman et al. (2006) — a GHRH analog modified to covalently bind serum albumin, dramatically extending its half-life from minutes to roughly a week. Most research peptide sources today sell the non-DAC "Mod GRF 1-29" version, which is shorter-acting but otherwise similar.

CJC-1295 is a GHRH (growth hormone-releasing hormone) analog. It binds pituitary GHRH receptors and extends the window during which the pituitary will release GH. It doesn't force a pulse — it primes the system. That's why it's typically paired with a GHRP like Ipamorelin, which fires the actual pulse.

Teichman et al. (2006) demonstrated dose-dependent increases in GH and IGF-1 in healthy adults with the DAC version, with a reasonable safety profile in short-term trials. Most other research is in livestock and animal models. Long-term human safety data is limited, which is the primary caveat for extended use.

Ipamorelin — the pairing is synergistic and is the standard GH secretagogue protocol. Both are typically dosed pre-sleep to amplify the natural nocturnal GH surge.

Developed by Novo Nordisk and published by Raun et al. (1998). Designed specifically as a cleaner GHRP — one that delivered the growth hormone release of older compounds like GHRP-6 without their side effects (hunger, prolactin and cortisol spikes).

Ipamorelin is a selective ghrelin receptor (GHS-R) agonist. It triggers a pituitary GH pulse with minimal effect on cortisol, prolactin, or ACTH — which is what differentiates it from the earlier GHRP generation. It works synergistically with GHRH analogs (CJC-1295, Sermorelin) because the two pathways converge on GH release through different mechanisms.

Raun et al. (1998) demonstrated clean GH release in rats and humans. Subsequent trials have examined post-operative ileus and gastrointestinal motility. Longer-term body composition and safety data in healthy adults is limited — most formal research focused on the GH-release pharmacology.

CJC-1295 or Sermorelin — the GHRP + GHRH pairing is the foundation of most GH secretagogue protocols. Also paired with Tesamorelin in more advanced protocols for stronger GH amplitude.

The 29-amino-acid N-terminal fragment of endogenous GHRH. Approved by the FDA in 1997 as Geref for pediatric growth hormone deficiency, making it one of the few GH secretagogues with a long regulatory history.

Sermorelin binds pituitary GHRH receptors and triggers endogenous pulsatile GH release — essentially the same mechanism the body uses naturally. Because it respects the body's feedback loops, it carries a lower risk of receptor desensitization or HPA disruption than exogenous GH. Half-life is short (~10 minutes), so dosing is typically pre-sleep to align with natural GH rhythms.

Extensive pediatric GHD literature supported FDA approval. Adult off-label use for age-related GH decline has smaller clinical evidence — primarily Walker et al. and related groups showing improved IGF-1, sleep quality, and body composition markers in older adults over 6–12 months of use.

Ipamorelin (GHRH + GHRP synergy — similar logic to CJC-1295 + Ipamorelin but with a shorter GHRH duration).

FDA-approved in 2010 as Egrifta for HIV-associated lipodystrophy (abnormal visceral fat accumulation in HIV patients on antiretroviral therapy). A modified GHRH(1-44) with an N-terminal trans-3-hexenoyl group that dramatically improves stability and half-life.

Like other GHRH analogs, Tesamorelin drives endogenous pulsatile GH release from the pituitary. Its distinguishing feature is efficacy — it produces larger, more sustained GH/IGF-1 increases than Sermorelin and has the cleanest human trial record for visceral fat reduction specifically.

Falutz et al. (2007, 2008, 2010) established efficacy for visceral adiposity reduction in HIV populations across multiple Phase 3 trials. Stanley et al. (2014) reported cognitive improvements (verbal memory, executive function) in older adults with age-related cognitive decline. Subsequent work has documented liver fat reduction in NAFLD. Among research peptides, Tesamorelin's human evidence base is among the strongest.

Often used alone given its potency. Can be paired with Ipamorelin for stronger pulse amplitude, though this is less necessary than with shorter-acting GHRHs.

Developed by Romano Deghenghi's group in the 1990s as a modified hexapeptide analog of GHRP-6 — specifically engineered for stronger GH-releasing activity and better oral/intranasal bioavailability than first-generation GHRPs.

Hexarelin is a ghrelin receptor (GHS-R) agonist — the same receptor Ipamorelin targets — but it produces a markedly larger GH pulse. It also binds CD36, a scavenger receptor on cardiac tissue, giving it direct cardioprotective effects independent of GH release. The tradeoff: Hexarelin is the GHRP most prone to tachyphylaxis — receptor desensitization with continuous use — so it's typically cycled aggressively rather than run long-term.

Locatelli et al. (1994) and Imbimbo et al. (1994) established potent GH release in animal and human studies. Torsello et al. (2003) and follow-up work by Broglio and Ghigo documented independent cardioprotective effects — reduced ischemia-reperfusion damage via CD36, not GH. Desensitization with chronic use has been well-characterized, limiting long-duration protocols.

CJC-1295 or Sermorelin (GHRH + potent GHRP for maximum pulse). Cycled use only — typically 2–4 weeks on, extended off, to avoid receptor desensitization.

Developed in the late 1980s by Francesco and colleagues as a modified IGF-1 analog initially intended for cell culture research. It acquired its name from its two structural changes: a 13-amino-acid N-terminal "Long" extension and an arginine ("Arg") substitution at position 3 of the native IGF-1 sequence. Those small changes transformed the molecule's pharmacokinetics dramatically.

Native IGF-1 circulates almost entirely bound to IGF-binding proteins (IGFBP-1 through -6), which protect it but also restrict when and where it acts. The Arg3 substitution disrupts binding to IGFBP-3 (the dominant carrier), leaving LR3 largely free in circulation. The N-terminal extension extends half-life from roughly 12 minutes (native IGF-1) to approximately 20–30 hours. The net effect: sustained, unrestricted IGF-1 receptor activation — driving the PI3K/Akt/mTOR pathway for protein synthesis, muscle hypertrophy, and hyperplasia (increased muscle cell count, not just size).

The compound was never developed for human therapeutic use, so formal human clinical trials don't exist. Native IGF-1 (Mecasermin/Increlex) is FDA-approved for severe primary IGF-1 deficiency and provides the closest translational evidence base. Animal studies show potent lean mass increases with LR3 (Tomas et al. 1992; Bailey et al. 1993). Its use in performance contexts is informed primarily by this preclinical work, native IGF-1 clinical data, and decades of off-label user experience — which is not the same as validated safety data.

Hypoglycemia — IGF-1 receptors have structural overlap with insulin receptors; large doses can cause significant blood glucose drops. Have fast carbs available.

Organ hypertrophy — IGF-1 drives growth in all tissues with IGF-1 receptors, not just muscle. Chronic high doses have been associated with gut wall thickening, cardiac hypertrophy, and visceral growth. Cycles should be short (4–6 weeks), not continuous.

Tumor promotion concerns — elevated IGF-1 signaling is a growth signal to any existing cancerous or precancerous tissue. This is an absolute contraindication for anyone with cancer history or elevated cancer risk.

CJC-1295 + Ipamorelin (endogenous GH pulse alongside direct IGF-1 signaling — the canonical advanced hypertrophy combination). BPC-157 supports tendon and connective tissue repair during aggressive hypertrophy phases, which often lag behind muscle growth. Not paired with other growth-heavy compounds given cumulative risk.

Identified by the Cohen lab at USC in 2015 (Lee et al.) as the first known mitochondrial-derived peptide — encoded in the mitochondrial 12S rRNA gene rather than the nuclear genome. Its existence rewrote assumptions about what mitochondria produce beyond energy.

MOTS-C activates AMPK — the cell's master energy-sensing kinase. Downstream effects include enhanced glucose uptake (independent of insulin), increased fatty acid oxidation, and improved metabolic flexibility. Endogenous MOTS-C levels decline sharply with age and with metabolic disease, which has positioned it as a candidate exercise-mimetic and longevity peptide.

Lee et al. (2015) demonstrated improved insulin sensitivity, exercise capacity, and metabolic profiles in aged mice. Reynolds et al. (2021) characterized the exercise-mimetic profile and showed training-like adaptations in sedentary animals. Human trials are early-stage but actively underway — CohBar and other groups have moved analogs into Phase 1/2 development.

SS-31 (membrane-level complement to biogenesis signal), NAD+ (provides the redox substrate for AMPK-driven metabolism). The SS-31 → MOTS-C → NAD+ stack is the canonical "mitochondrial" protocol.

Developed by Hazel Szeto and Peter Schiller around 2004 as part of a series of cell-penetrating antioxidant peptides. Stealth Biotherapeutics licensed it as Elamipretide and has moved it through multiple late-stage clinical trials for mitochondrial disease.

SS-31 is a cationic tetrapeptide that concentrates selectively on the inner mitochondrial membrane by binding cardiolipin — a phospholipid that holds the electron transport chain in its proper cristae geometry. Stabilizing cardiolipin restores efficient ETC organization, reduces electron leak, and lowers reactive oxygen species production at the source rather than mopping them up downstream.

Human clinical trials are unusually advanced for this class. Sabbah et al. (2016) showed improvements in heart failure patients. Karaa et al. (2020) reported vision improvements in Leber hereditary optic neuropathy. Phase 3 trials have covered primary mitochondrial myopathy and Barth syndrome with mixed but informative results. Preclinical work covers ischemia-reperfusion injury, kidney disease, and neurodegeneration.

MOTS-C (SS-31 stabilizes the existing machinery; MOTS-C builds new machinery), NAD+ (redox substrate for the stabilized ETC). Typically introduced first in a mitochondrial stack to establish the membrane foundation.

Identified by Arthur Harden and William Young in 1906 as a "coferment" required for yeast fermentation — the first coenzyme ever characterized. A century of work has since established it as fundamental to virtually all cellular energy metabolism and a central molecule in aging research.

NAD+ is an electron carrier in the mitochondrial electron transport chain and the required substrate for sirtuins (SIRT1–SIRT7), PARPs (DNA repair), and CD38. Cellular NAD+ levels decline substantially with age, and that decline impairs mitochondrial function, DNA repair, and circadian signaling. Injectable NAD+ delivers the intact molecule directly rather than relying on precursor conversion.

The underlying biology is extensively characterized across thousands of papers. Precursor trials (NMN, NR) have shown raised blood NAD+ levels and some metabolic benefits in human trials. Direct subcutaneous/IV NAD+ has less formal trial data but a long history of clinical use in addiction medicine and increasingly in longevity clinics. The gap between mechanistic strength and formal trial coverage is the main caveat.

SS-31 and MOTS-C (complete mitochondrial stack — NAD+ provides the fuel for improved ETC function), Glutathione (redox + antioxidant synergy).

Characterized by Frederick Gowland Hopkins in 1921 as a thiol-containing tripeptide of glutamate, cysteine, and glycine. Decades of subsequent work established it as the primary intracellular antioxidant in essentially every human cell and a central cofactor in phase II liver detoxification.

Glutathione works through its active thiol (-SH) group, directly neutralizing reactive oxygen species and serving as the substrate for glutathione peroxidases (GPx) and glutathione-S-transferases (GST) — enzymes responsible for clearing peroxides and conjugating toxins for excretion. Intracellular levels drop under oxidative stress, chronic inflammation, alcohol exposure, acetaminophen toxicity, and normal aging. Injectable/IV glutathione bypasses the GI breakdown that limits oral absorption.

Sechi et al. (1996) reported symptom improvement in Parkinson's disease with IV glutathione. Honda et al. (2017) documented ALT improvements in NAFLD patients with oral glutathione, and IV protocols have small-scale trial support for oxidative conditions. In dermatology, multiple trials have examined IV glutathione for skin lightening with variable results. Subcutaneous dosing is widely used clinically but has less formal trial coverage than IV.

NAD+ (redox/antioxidant synergy), mitochondrial stacks generally, and recovery/detox protocols following high-stress or high-training phases.

Developed by Eli Lilly; entered Phase 2 clinical trials around 2022. Built on the GLP-1/GIP dual agonist framework pioneered by Tirzepatide, with a third activity added at the glucagon receptor.

Retatrutide is a single molecule that activates all three receptors: GLP-1 (appetite suppression, insulin sensitivity), GIP (insulin response, fat metabolism), and glucagon (increased energy expenditure, hepatic fat mobilization). The glucagon arm is what differentiates it — it adds thermogenic and lipolytic activity on top of the appetite-suppression effects of the GLP-1/GIP duo.

Jastreboff et al. (NEJM 2023) reported the Phase 2 trial: approximately 24% body weight loss at 48 weeks at the highest dose in adults with obesity — the largest reduction of any GLP-class agent to that point. Additional trials have documented hepatic fat reduction in NAFLD. Phase 3 trials are ongoing. Titrate slowly; GI side effects are dose-limiting.

CJC-1295 + Ipamorelin (muscle preservation during aggressive fat loss), MOTS-C (improved cellular fuel utilization), AOD-9604 (targeted lipolysis).

Developed by Eli Lilly; FDA-approved in 2022 as Mounjaro for type 2 diabetes, and subsequently as Zepbound for chronic weight management. The first dual GLP-1/GIP agonist to reach market.

A single peptide that activates both GLP-1 and GIP receptors. GLP-1 suppresses appetite, slows gastric emptying, and improves insulin secretion. GIP enhances insulin response and influences fat storage — and the combination appears more effective than either alone for body composition.

The SURPASS trials (type 2 diabetes) and SURMOUNT trials (obesity) established efficacy and safety across large populations. SURMOUNT-1 reported roughly 21% body weight loss at the highest dose at 72 weeks. Real-world and subgroup data continue to accumulate given approval status.

CJC-1295 + Ipamorelin (muscle preservation during fat loss), AOD-9604 (targeted fat mobilization on top of systemic effect).

Developed by Novo Nordisk as the successor to liraglutide. FDA-approved in 2017 as Ozempic for type 2 diabetes and in 2021 as Wegovy for chronic weight management. The molecule is engineered for once-weekly dosing via fatty-acid acylation that binds serum albumin and resists DPP-4 degradation.

Semaglutide is a GLP-1 receptor agonist. It suppresses appetite at hypothalamic centers, slows gastric emptying (which prolongs satiety), improves glucose-dependent insulin secretion, and reduces glucagon release. Unlike the dual/triple agonists that followed it, Semaglutide is single-receptor — simpler pharmacology, extensive safety data, but lower peak efficacy for weight loss than Tirzepatide or Retatrutide.

The SUSTAIN trials established efficacy and safety in type 2 diabetes. The STEP program (STEP-1 through STEP-5) documented roughly 15% body weight loss at 68 weeks in adults with obesity. The SELECT trial (2023) showed reduced major adverse cardiovascular events in overweight/obese patients with established cardiovascular disease — a landmark finding that extended the indication beyond metabolic effects.

CJC-1295 + Ipamorelin (lean mass preservation during caloric deficit), MOTS-C (cellular metabolic support), AOD-9604 (targeted lipolysis).

Developed at Monash University in the 1990s as a modified C-terminal fragment of human growth hormone (residues 177–191). The goal was to isolate GH's fat-burning activity from its growth and insulin-sensitivity effects.

AOD-9604 selectively activates hormone-sensitive lipase and enhances fat oxidation without binding the GH receptor at meaningful levels. That means it doesn't raise IGF-1, affect blood glucose, or produce the growth effects of full-length GH — it isolates the lipolytic activity. Most effective in fasted state.

Heffernan et al. (2001) documented fat mass reduction in mouse models. Human Phase 2 trials showed modest and variable weight loss effects — not on the scale of GLP-class agents — which has positioned AOD-9604 as a supporting compound rather than a primary fat-loss agent in most modern protocols.

Retatrutide or Tirzepatide (targeted lipolysis on top of systemic appetite suppression), MOTS-C (cellular fat oxidation support), CJC-1295 + Ipamorelin.

A small-molecule inhibitor developed in the mid-2010s at the University of Texas Southwestern (Neelakantan et al.) as a tool to probe NNMT — nicotinamide N-methyltransferase — an enzyme overexpressed in adipose and liver tissue in obesity and metabolic disease. Technically a small molecule rather than a peptide, but commonly used alongside peptide protocols for its metabolic effects.

5-Amino-1MQ inhibits NNMT. Normally NNMT consumes methyl groups (SAM) and nicotinamide (an NAD+ precursor) to produce 1-methylnicotinamide. Blocking it raises cellular SAM and NAD+, shifts adipocytes toward fat oxidation, and improves metabolic flexibility. Effectively, it un-throttles the NAD+ salvage pathway in fat tissue specifically.

Neelakantan et al. (2018, 2019) showed reduced adipose mass and improved glucose handling in diet-induced obese mice without calorie restriction. Additional preclinical work covers NAFLD and sarcopenia. No human clinical trial data exists — this is an early-stage research compound with a strong mechanistic case but no translational evidence yet.

Theoretical stacks with MOTS-C and NAD+ (converging on NAD+ availability and AMPK activation) or GLP-class agents (independent mechanism, potential additive fat loss). Pairings are mechanistic rather than trial-validated.

Developed at Saint Louis University by Thomas Burris's lab as a pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ). Published in 2023 and widely covered as a potential "exercise-in-a-pill" mimetic. Technically a small molecule, not a peptide — included here because it's frequently discussed alongside metabolic peptides.

ERRs are transcription factors that govern mitochondrial biogenesis, oxidative phosphorylation, and fatty-acid oxidation in skeletal muscle. Exercise upregulates their activity. SLU-PP-332 activates them pharmacologically, driving the same gene-expression program — increased mitochondrial content, oxidative fiber-type shift, and enhanced endurance capacity — without the physical work of training.

Billon et al. (2023) reported that SLU-PP-332 increased running endurance in mice by roughly 70% and produced significant fat loss in diet-induced obesity models without changes in food intake or physical activity. No human data exists. Safety, dosing, and long-term effects in humans are entirely unknown. Strictly experimental.

Theoretical synergy with MOTS-C (converging on mitochondrial biogenesis) and SS-31 (membrane stabilization of newly built mitochondria). Pairings are entirely hypothesis-level given the absence of human trials.

Developed in Russia in the 1990s at the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology. Designed as a stable synthetic analog of tuftsin — an endogenous immunomodulatory peptide — with modifications aimed at anxiolytic activity.

Selank modulates GABA-A signaling (similar direction to benzodiazepines but without the receptor binding or dependence profile), influences serotonergic tone, and increases BDNF expression. The net effect is anxiolytic without sedation — it takes the edge off without dulling cognition or causing tolerance.

Russian clinical trials (Medvedev, Zozulya and colleagues through the 2000s) documented efficacy in generalized anxiety disorder with a favorable side-effect profile. Preclinical work has covered memory enhancement, stress resilience, and immunomodulation — including intranasal influenza models. Western trial data is sparse, which is the main caveat.

Semax — the classic pairing; Semax sharpens cognition while Selank calms reactivity, producing focused clarity rather than stimulation.

Developed in the Soviet Union in the 1980s by Ashmarin and colleagues at Moscow State University. Based on the ACTH(4-10) fragment, modified to strip out hormonal (cortisol-stimulating) activity while preserving the neurotropic effects. Approved in Russia for stroke recovery and other neurological conditions.

Semax upregulates BDNF and NGF — neurotrophic factors tied to neuroplasticity and cognition. It also modulates dopaminergic and serotonergic tone. Effects are typically described as sharper focus, better memory consolidation, and improved mental stamina, without the crash profile of classical stimulants.

Russian clinical trials documented improved recovery after ischemic stroke when Semax was added to standard care, and it has regulatory approval there for that indication. Additional trials cover ADHD, optic nerve conditions, and cognitive performance. As with Selank, the Western randomized trial base is thin and is the primary caveat.

Selank — the Semax (signal) + Selank (noise reduction) combination is the standard cognitive stack.

Isolated in 1977 by Marcel Monnier and Guido Schoenenberger at the University of Basel. The peptide was identified in cerebral venous blood of rabbits during electrically-induced delta-wave sleep — hence the name. It's a nine-amino-acid sequence that has remained somewhat enigmatic: clearly bioactive, but with a mechanism that still isn't fully characterized.

DSIP's exact molecular targets are not fully mapped. Evidence points to modulation of GABAergic tone, influence on hypothalamic-pituitary signaling (ACTH and GH), and interaction with opioid systems. Effects reported include promotion of slow-wave sleep architecture, attenuation of stress responses, and blunting of opioid withdrawal symptoms. It is not a sedative in the classical sense — it shifts sleep toward deeper phases rather than inducing drowsiness.

Small human studies from the 1980s (Schneider-Helmert, Kaeser) reported improvements in chronic insomnia, stress-related sleep disturbance, and opioid/alcohol withdrawal. Animal studies have covered stress resilience, analgesia, and neuroprotection. The literature is moderate in volume but thin in large randomized trial data — it's a peptide with a long history and relatively modest evidence base for its age.

Selank (anxiety-driven sleep disruption), CJC-1295 + Ipamorelin (pre-sleep GH pulse alongside deeper sleep architecture), Epitalon in longevity-oriented protocols.

Developed from Melanotan II (a tanning peptide) when researchers noticed a striking off-target effect — sexual arousal. FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

PT-141 is a non-selective melanocortin receptor agonist, primarily at MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors (Viagra, Cialis), it doesn't work through vascular dilation — it acts on the brain's arousal circuitry directly. That's why it works in both men and women, and in cases where vascular-based drugs don't.

Multiple Phase 2 and Phase 3 trials established efficacy for female HSDD, leading to FDA approval. Earlier trials examined male erectile dysfunction with positive but modest effects. The main side effect is nausea, which is dose-dependent — and flushing, which is common.

Typically used standalone. Timing (45–90 minutes pre-activity) matters more than stacking for this compound.

The parent KISS1 gene was identified in 1996 in Hershey, Pennsylvania as a metastasis suppressor — the name comes from Hershey's famous "Kisses" chocolates. Its role as the master regulator of reproductive endocrinology was not recognized until the early 2000s, when loss-of-function mutations in its receptor (GPR54/KISS1R) were shown to cause hypogonadotropic hypogonadism (de Roux 2003; Seminara 2003). Kisspeptin-10 is the shortest biologically active fragment of the full kisspeptin peptide.

Kisspeptin is the upstream trigger of the entire hypothalamic-pituitary-gonadal (HPG) axis. It binds KISS1R on hypothalamic neurons that then release GnRH (gonadotropin-releasing hormone), which drives the pituitary to secrete LH and FSH, which in turn stimulate testicular testosterone production in men and ovarian steroidogenesis and ovulation in women. Kisspeptin-10 administration produces a physiological LH/testosterone rise through the body's own pathway rather than exogenous hormone replacement.

Waljit Dhillo's group at Imperial College London has led the human research. Dhillo et al. (2005) first demonstrated dose-dependent LH/testosterone release in healthy men. Chan et al. (2014) extended the work to hypogonadotropic hypogonadism. Abbara et al. have published extensively on kisspeptin as an ovulation trigger in IVF (with lower OHSS risk than hCG) and more recently on sexual response and mood. Trials for male hypoactive sexual desire and post-finasteride syndrome are ongoing. The human evidence base for a "research peptide" is unusually substantial.

Typically used standalone given its upstream role. Research protocols sometimes combine it with PT-141 for sexual response (different mechanisms — central arousal vs. HPG axis activation).